Mereo BioPharma (MREO) Tax Provisions (2023 - 2025)

Mereo BioPharma (MREO) has reported Tax Provisions for 3 consecutive years, with $10.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Tax Provisions fell 4.13% year-over-year to $10.4 million; the TTM figure through Mar 2026 stood at $10.4 million (down 4.13% YoY), while the FY2025 annual figure was $10.4 million, down 4.13% from the prior year.
• Tax Provisions fell to $10.4 million in Q4 2025 per MREO's latest filing, from $10.9 million in the prior quarter.
• Across five years, Tax Provisions topped out at $10.9 million in Q4 2024 and bottomed at -$532000.0 in Q4 2023.
• Historically, Tax Provisions has averaged $6.9 million across 3 years, with a median of $10.4 million in 2025.
• Annual changes were most pronounced in 2024 — Tax Provisions jumped 2141.92% — and 2025, when it declined 4.13%.
• Mereo BioPharma's Tax Provisions stood at -$532000.0 in 2023, then surged by 2141.92% to $10.9 million in 2024, then decreased by 4.13% to $10.4 million in 2025.
• Business Quant data shows MREO's Tax Provisions at $10.4 million in Q4 2025, $10.9 million in Q4 2024, and -$532000.0 in Q4 2023.